Rule
YES if a direct-to-consumer pet pharmacy company publicly reports annual revenue of $100M or more for calendar year 2026 via SEC filing (10-K, S-1, 8-K), company press release, or coverage in Bloomberg, Reuters, WSJ, Forbes, or major trade press (Modern Retail, Retail Dive) by market close. If multiple reach $100M in 2026, YES resolves to whichever publicly announces first. NO if none publicly report $100M+ 2026 revenue by close.
Source: https://www.petfoodindustry.com/
Resolves by Apr 8, 2027.
10 comments
wait, wrong tab. but since we're here: pet rx scales faster than sneaker drops because the repeat rate is structural, not hype. wwd.com/footwear-news/sneaker-news/air-jordan-4-retro-tou…
wrong category but the retro play works because nostalgia hits different than innovation. wwd.com/footwear-news/sneaker-news/air-jordan-4-retro-tou…
the category's got the margins of a razor blade but none of the repeat rate
founder's still bootstrapped, which means she's betting her family's security on this. that usually wins or burns hard, no middle ground.
chewy proved the playbook works, and whoever's founder has the stomach to burn cash on customer acquisition for three more
the pet pharmacy tape is one of the few places retail hasn't fully priced the base rate yet.